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Additional Methods  
Materials 
CytoPainter Phalloidin iFluor555 and Gö6976 were from Abcam (Cambridge, U.K.). Ro-
0437626 was obtained from Tocris Bioscience (Bristol, U.K.). MeSAMP and MRS-2179 were 
from Sigma Aldrich (Gillingham, U.K.). Ketanserin was from Axxora (Nottingham, UK). All 
other reagents were of analytical grade. 
F-actin Measurements 
F-actin measurements were performed according to the method of Rosado et al., (2000). 
Briefly, unstimulated washed platelets were treated with either 100 µM nicergoline or its 
vehicle, DMSO, for 5 minutes at 37°C.  Cells were then fixed by addition of 3% [w/v] 
formaldehyde and stored at 4°C until use.  Platelets were collected by centrifugation and then 
permeabilised by incubation in Phosphate-buffered saline (PBS) containing 0.1% Triton X-100 
and 1 mg/mL bovine serum albumin for 10 minutes at room temperature. Cells were recollected 
by centrifugation and resuspended in PBS containing 1 µM CytoPainter Phalloidin iFluor555 
and 1mg/mL BSA and incubated at room temperature for 30 minutes.  Cells were recollected 
by centrifugation and finally resuspended in PBS containing 1 mg.mL-1 BSA. 100 μL aliquots 
of each sample were plated into 96 well plates in either duplicate or triplicate.  Fluorescence 
was then recorded using a BioTek Synergy 2 microplate reader using a 540 nm excitation 
wavelength and collected using a 590 nm emission filter. The mean of the replicates was then 
recorded for each sample.  
Single platelet imaging  
Fixed platelet samples for analysis of the actin structure of cells were prepared as above for the 
F-actin measurements. Platelet microtubule structure was monitored in cells loaded with 1 µM 
Fluo-5N/AM for 2 hours at 37°C in PRP (Sage et al., 2011). After dye loading cells were 
washed by centrifugation and resuspended in supplemented HBS.  Cells were preincubated 
with 100 µM nicergoline (or its vehicle, DMSO) under magnetic stirring for 5 minutes at 37°C. 
Chambered slides (Ibidi µ-slide 8 well) were coated with a poly-L-lysine solution (Sigma 
Aldrich, UK) overnight at 4°C. Slides were washed with either supplemented HBS (Fluo-5N) 
or PBS (Phalloidin) and mounted on the microscope stage. Platelet suspensions at a density of 
2 × 108 mL−1 were pipetted into the chambered coverslip and allowed to adhere to the substrate 
for 3 min. Excess platelet suspension was then removed and the slides washed twice with either 
supplemented EGTA to which 1 mM EGTA was added (Fluo-5N) or PBS (Phalloidin).  
Fluorescence was monitored using a Fluoview FV1200 laser-scanning confocal microscope 
(Olympus, U.K.) with a PLAPON 60× oil immersion objective. Images were recorded at a 
frequency of 0.5 Hz for 5 min excitation at 473 nm (Fluo-5N) or 543 nm (CytoPainter 
Phalloidin iFluo555) and emission at 490–520 nm or 590-620nm respectively. 
Dense granule Secretion 
For the Gö6976 experiments, luciferin-luciferase luminescence measurements were made 
using a using a BioTek Synergy 2 microplate reader on 100 μL aliquots of washed human 
platelet suspension dispensed into 96 well plates, to which 10% [v/v] luciferin-luciferase was 
added.  Thrombin-evoked secretion was measured as the thrombin-evoked increase in 
luminescence collected for 1 minute after thrombin addition when compared to the basal 
reading taken immediately prior to thrombin stimulation 
Results  
Nicergoline does not itself elicit a Ca2+ signal, but does trigger a small reduction in resting 
[Ca2+]cyt in both the presence and absence of extracellular Ca2+ 
Experiments were performed to examine the effect of nicergoline on resting [Ca2+]cyt in cells 
treated in the presence and absence of extracellular Ca2+. As shown in Supplementary Figure 
1, addition of nicergoline itself elicited no increase in [Ca2+]cyt, but it did decelerate the rate of 
increase in the reported [Ca2+]cyt in the presence of extracellular Ca
2+ (Figure S1A; ∆[Ca2+]cyt 
= 15.3 ± 2.0 nM and 10.9 ± 2.2 nM for DMSO- and nicergoline-treated cells respectively; n = 
5; P < 0.05)  and accelerated the slow rate of decline seen in the absence of extracellular Ca2+ 
(Figure S2A,B; ∆[Ca2+]cyt = 2.3 ± 0.8 nM and 6.2 ± 0.8 nM for DMSO- and nicergoline-treated 
cells respectively; n = 5; P < 0.05) – consistent with a small but consistent effect of nicergoline 
on resting [Ca2+]cyt. In the experiments performed in the absence of extracellular Ca
2+, thrombin 
was added at the end of the 10 minute preincubation to act as a positive control of nicergoline 
activity. In these experiments nicergoline was found to reduce the thrombin-evoked rise in 
[Ca2+]cyt to  76.7% ± 3.9% of control (n = 6; P < 0.05). 
Nicergoline causes a slight thickening of the cortical F-actin layer without altering the 
polymerisation state of F-actin within the platelets 
In addition to the tubulin cytoskeleton, platelets also contain an extensive actin cytoskeleton 
which plays a key role in triggering morphological changes upon activation and adhesion to 
the damaged vascular wall. Further experiments therefore examined the effect of nicergoline 
pretreatment on the F-actin content and distribution in human platelets.  Cells were fixed, 
permeabilised and F-actin was labelled with fluorescently-labelled phalloidin.  Measurements 
of F-actin content revealed that nicergoline induced no significant change in polymerised F-
actin content in these cells (102.5% ± 7.7% of control; n = 5; P > 0.05), suggesting that 
nicergoline does not trigger active rearrangement of this cytoskeletal structure within the cells.   
Platelets labelled with fluorescently-labelled phalloidin were examined using confocal 
microscopy to investigate the distribution of actin in nicergoline-treated cells. Fixed control 
platelets were found to principally exit in a discoid form, with cells seen to take a range of 
either thin discs or circular forms depending on which side of the platelet the cells had settled 
on the surface of the coverslide.  In contrast, fixed nicergoline-treated platelets were found to 
exist as a near-homogenous population of rounded cells (Figure S2) suggesting that cells had 
changed from their discoid form into a spherical form, as previous observed by Le Menn et al., 
(1979). The observation that fixed nicergoline-treated platelets plated onto coverslips appear 
spherical, whilst live cells appear similar to the control cells, suggests that platelets are able to 
spread similarly to control cells through remodelling of their cortical F-actin layer. 
Unlike its effect on the cortical microtubule bundle, nicergoline pretreatment was found to 
leave the cortical actin ring intact.  However further examination of this structure found that 
the cortical F-actin layer was more pronounced in these cells compared to control cells (Figure 
3B), with the cortical actin layer  observed to be slightly thickened in nicergoline-treated 
platelets (308 nm ± 11 nm compared to 235 nm ± 6 nm in control cells; n = 5; P < 0.05). These 
results suggest that F-actin content is also redistributed in response to the nicergoline-induced 
disruption of the cortical microtubule bundle.  This would be in line with previous work by 
Cerecedo et al., (2008), who found that disrupting actin or microtubule structure in platelets 
could simultaneously affect the organisation of the unaffected cytoskeletal component.  
  
Figure S1: Nicergoline does not itself elicit a Ca2+ signal, but does trigger a small reduction in the baseline 
[Ca2+]cyt in both the presence and absence of extracellular Ca2+. Fura-2-loaded human platelets were suspended 
in supplemented HBS containing 200 μM CaCl2 and prewarmed for 5 minutes at 37°C prior to testing. (A) 
Platelets were stimulated with 100 μM nicergoline or an equal volume of its vehicle, DMSO in the presence of 
continuous magnetic stirring. (B,C) 1 mM EGTA was added before the cells were treated with either 100 μM 
nicergoline or its vehicle for 10 min at 37°C in the presence of continuous magnetic stirring. Platelets were then 
stimulated with 0.5 U.mL-1 thrombin. (C) is an expanded view of the signals observed after nicergoline treatment 







Figure S2: Nicergoline causes a slight thickening of the cortical F-actin layer without altering the 
polymerisation state of F-actin within the platelets. Platelets were treated with either DMSO (upper panels) or 
100 μM nicergoline (lower panels) for 5 min at 37°C in the presence of continuous magnetic stirring. Cells were 
then fixed, permeabilised and incubated with Cytopainter Phalloidin iFluor555 to indicate the presence of F-actin.  
Platelets were washed and allowed to settle on poly-L-lysine coverslips for 5 minutes prior to imaging. Excess 
platelet suspension was removed and the slides were washed twice with Phosphate-buffered saline.  Fluorescence 
was then monitored using an Olympus Fluoview FV1200 confocal microscope. The right-hand panels show the 
overlay of transmitted light image and fluorescence from the Cytopainter Phalloidin iFluor555; the lower panels 
show the fluorescence from TubulinTracker alone. The results presented are representative of 5 experiments. 
 
  
Nicergoline triggers a reorganisation of the intracellular Ca2+ stores  
The effect of nicergoline on intracellular Ca2+ store location, was monitored in resting Fluo-
5N-loaded platelets treated with either nicergoline or DMSO. Consistent with our previous 
findings (Sage et al., 2011), control platelets were observed to have an inhomogeneous, 
punctate distribution of intracellular Ca2+ stores (Figure S3A,B). In contrast, nicergoline-
treated platelets had a more homogenous Ca2+ store distribution with no obvious punctae of 
raised fluorescence observed (Figure S3C,D). Homogeneity of the Fluo-5N fluorescence under 
both conditions was quantitatively assessed by comparing the variance in Fluo-5N pixel 
fluorescence from treated and untreated cells, with the mean standard deviation being 8.4 ± 0.2 
arbitrary units  for nicergoline-treated platelets compared to 12.8 ± 0.6 arbitrary units in 
DMSO-treated platelets (both n = 8; P < 0.05). The loss of punctae in nicergoline-treated cells 
lead to a reduction in the maximum pixel fluorescence of the cell  when compared to that 
observed in DMSO-treated cells (63.9% ± 1.6% of control; n = 8;  P < 0.05). In contrast mean 
Fluo-5N fluorescence of the cells were found to be unaffected (96.3% ± 13.9% of control; n = 
8; P > 0.05). A linescan analysis of 3 of the cells shown was also performed (Figure S3E) – 
these showed that whilst there was a comparable basic level in the nicergoline- and DMSO-
treated cells, there were one or two significant peaks in Fluo-5N fluorescence observed in every 
DMSO-treated cell that were not seen in nicergoline-treated cells. These data therefore suggest 
that whilst the amount of Ca2+ stored inside these cells is not altered by nicergoline treatment, 
the distribution of the stored Ca2+ is significantly altered, presumably due to microtubule-
associated reorganisation of the DTS.  
Nicergoline elicits no additional inhibitory effect when pericellular Ca2+ accumulation is 
prevented by pretreatment with an NCX inhibitor. 
In our previous study we have demonstrated that pericellular Ca2+ accumulation is dependent 
upon the forward mode exchange activity of the NCX (Sage et al., 2013). If nicergoline works 
via interrupting pericellular Ca2+ recycling in human platelets, blocking the NCX with its 
inhibitor KB-R7943, should prevent further nicergoline-induced inhibition of the thrombin-
evoked Ca2+ signal.   As shown in Figure S4, Ca2+ release as previously observed (80.4% ± 
1.9% of control and 32.2% ± 3.5% of control for nicergoline or KB-R7943 alone; n = 6; P < 
0.05).  Pretreatment with both inhibitors together did not reduce the thrombin-evoked Ca2+ 
signal further when compared to the effect KB-R7943 alone  (43.6% ± 4.3% of control; n = 6; 
P < 0.05 when compared to both control cells and cells treated with KB-R7943 alone).  Our 
data showed that nicergoline treatment alongside KB-R7943 actually significantly potentiated 
the thrombin-evoked Ca2+ signal seen in NCX-inhibited cells. These data suggests that 
nicergoline inhibits thrombin-evoked rises in [Ca2+]cyt  by reducing the efficacy of the 
pericellular recycling system.  
The nicergoline-induced potentiation of the Ca2+ signals in KB-R7943-treated cells was an 
unexpected finding and suggests that redistribution of the intracellular stores may delocalise 
Ca2+ release from the dense tubular system from another Ca2+ removal or sequestration 
mechanism preventing effective Ca2+ transport out of the cytosol. We have previously 
suggested that the plasma membrane Ca2+-ATPase (PMCA) may contribute to pericellular 
recycling as this transporter is localised within the OCS in close proximity to the DTS in 
platelets (Cutler et al., 1980), and treatment with PMCA inhibitors reduced agonist-evoked 
Ca2+ signals and dense granule secretion (Jones et al., 2010).   In nicergoline-treated cells, 
dissociation of the DTS from the OCS may therefore also reduce the efficacy of the PMCA in 
removing Ca2+ following thrombin-evoked Ca2+ rises. Further work will be needed to examine 
this hypothesis further.   
 Figure S3: Nicergoline triggers reorganisation of the subcellular location of the intracellular Ca2+ stores. 
Fluo-5N-loaded platelets were suspended in supplemented HBS.  Cells were pretreated with either DMSO (A,B) 
or 100 μM nicergoline (C,D) for 5 min at 37°C in the presence of continuous magnetic stirring. The platelets were 
then added to a poly-L-lysine-coated chambered slide, and allowed to settle for 3 minutes. Excess platelet 
suspension was removed and the slides were washed twice with Ca2+-free HBS. Fluorescence was then monitored 
using an Olympus Fluoview FV1200 confocal. Images for Fluo-5N alone (A,B) or overlaid with the transmitted 
light image (C,D) are shown. Scale bar in bottom left corner indicates 5 µm. (E) A Linescan analysis of the 3 
numbered cells indicated in (B,D). The yellow lines indicated where the line scan analysis was performed.  Results 







Figure S4: Nicergoline elicits no additional inhibitory effect when pericellular Ca2+ accumulation 
is prevented by pretreatment with an NCX inhibitor. Fura-2-loaded human platelets were suspended 
in supplemented HBS. Platelets were pre-treated with either 100 μM nicergoline or an equal volume of 
its vehicle (DMSO) for 5 min at 37°C in the presence of continuous magnetic stirring. Cells were then 
treated with either 50 μM KB-R7943 for 5 additional minutes at 37°C. 1 mM EGTA was then added 




The inhibitory effect of nicergoline on thrombin-evoked Ca2+ signalling is not caused by a 
reduction in autocrine signalling.  
Previously, our group and others have found that blocking autocrine-mediated signalling can 
reduce thrombin-evoked Ca2+ release (Lages and Weiss, 1999; Sage et al., 2013). The finding 
that nicergoline can significantly reduce thrombin-evoked dense granule secretion, therefore 
raises the question as to whether reduced dense granule secretion is the cause, and not the 
effect, of the reduced thrombin-evoked Ca2+ signal. If thrombin-evoked Ca2+ signalling was 
dependent upon the IP3-mediated release of Ca
2+ from intracellular stores triggered by ADP or 
serotonin, then blocking autocrine signalling in these cells should prevent thrombin-evoked 
Ca2+ release. As can be seen in Figure S5A, combined inhibition of P2X1, 5-HT2A, P2Y1 and 
P2Y12 receptors was found to potentiate and not inhibit, the net release of Ca
2+ from intracellular 
stores (128.8% ± 3.4% of control; n = 6; P < 0.05).  These results suggest that autocrine 
stimulation of platelets is not responsible for facilitating thrombin-evoked Ca2+ release from 
the intracellular stores. Instead the greater depletion is indicative of a failure to refill the Ca2+ 
stores as effectively – hence leading to the increased depletion observed here. In addition, as 
nicergoline inhibits the primary Ca2+ release, whilst autocrine signalling blockers do not, these 
results suggest that nicergoline works to principally inhibit thrombin-evoked Ca2+ signalling, 
which as a consequence prevents dense granule secretion.  
These results do beg the question on what role autocrine signalling does play in mediating 
thrombin-evoked Ca2+ signalling.   Previous work on human subjects with delta storage pool 
disorder demonstrated that autocrine stimulation of platelets was principally required to 
maintain the opening of divalent cation channels (Lages & Weiss, 1999).  In addition, we 
demonstrated that preventing pericellular recycling of Ca2+ back into the cytosol by blocking 
non-selective cation channels could reduce thrombin-evoked rises in [Ca2+]cyt, as well as 
prevent refilling of intracellular Ca2+ stores leading to them becoming more depleted (Sage et 
al., 2013).  Therefore Mn2+ quench experiments were performed to examine whether blocking 
autocrine stimulation of platelets prevented opening of non-selective cation channels in 
thrombin-stimulated platelets. As shown in Figure S5B, combined inhibition of all autocrine 
signalling reduced thrombin-evoked Mn2+ quench to 78.4± 4.3% of control (n = 6; P < 0.05).  
These results confirms that autocrine signalling does not mediate its effect on thrombin-evoked 
signalling through assisting in the depletion of the intracellular Ca2+ stores, but instead works 
to open Ca2+-permeable ion channels to allow Ca2+ recycling to contribute to the cytosolic Ca2+ 
signal, which in turn facilitates intracellular Ca2+ store refilling.   These results therefore 
demonstrate that nicergoline’s inhibitory effect on thrombin-evoked Ca2+ signalling is not 
principally due to loss of autocrine signalling from the platelet dense granules.  
  
 Figure S5: Nicergoline-induced inhibition of thrombin-evoked Ca2+ signalling is a cause, and not a 
consequence, of the nicergoline-related inhibition of dense granule secretion. (A)Fluo-5N-loaded human 
platelets were suspended in supplemented HBS. Platelets were pre-treated with either the autocrine inhibitors (25 
μM Ro-0437626, 50 μM Ketanserin, 75 μM MRS-2179 and 100 μM MeSAMP), or an equal volume of their 
vehicles, DMSO, for 5 min at 37°C. 1 mM EGTA was added before the cells were stimulated with 0.5 U.mL-1 
thrombin. The results presented are representative of 6 experiments.  (B) Fura-2-loaded platelets suspended in 
Ca2+-free HBS supplemented with 0.1 U.mL-1 apyrase were preincubated with either the autocrine inhibitors (25 
μM Ro-0437626, 50 μM Ketanserin, 75 μM MRS-2179 and 100 μM MeSAMP), or an equal volume of their 
vehicles, DMSO, for 5 min at 37°C. Extracellular Ca2+ was chelated by addition of 500 μM EGTA, followed 30 
seconds later by 1 mM MnCl2. Platelets were stimulated 30s later with 0.5 U mL-1 thrombin. (C) Fura-2-loaded 
human platelets were suspended in supplemented HBS. Platelets were pre-treated with either 3 μM Gö6976 for 
10 min at 37°C or an equal volume of its vehicle (DMSO) for 10 min at 37°C. 1 mM EGTA was then added before 
cells were stimulated with 0.5 U.mL-1 thrombin. The results presented are representative of 6 experiments. (D) 
Cells were pretreated with 3 μM Gö6976 for 10 min at 37°C. The platelets were then added to a poly-L-lysine-
coated chambered slide, and allowed to settle for 3 minutes. Excess platelet suspension was removed and the 
slides were washed twice with Ca2+-free HBS containing 1 mM EGTA and 2.5 Fluo-4 K+ salt, and platelets were 
then stimulated by addition of 0.5 U.mL-1 thrombin. Fluorescence was then monitored using an Olympus Fluoview 
FV1200 confocal microscope at 0.5Hz for 5 minutes. The image shows 2 Gö6976-treated cells both showing the 
simultaneous expression of pericellular Ca2+ hotspots (yellow arrows) (A-D) The results presented are 
representative of 6 experiments.  
  
 Ca2+ accumulation in the pericellular Ca2+ hotspot occurs in the absence of dense granule 
secretion. 
As platelet dense granules are known to contain a high concentration of Ca2+ (Ruiz et al., 2004), 
nicergoline inhibition of the pericellular Ca2+ hotspot, and thus thrombin-evoked Ca2+ release, 
might be due to the cells inability to exocytose Ca2+ into the pericellular space. Previous work 
has demonstrated that the conventional PKC isoform-selective inhibitor Gö6976 can abolish 
thrombin-evoked dense granule secretion (Strehl et al., 2007). Experiments were therefore 
performed to examine the effect of the conventional PKC inhibitor Gö6976 on thrombin-
evoked dense granule secretion and cytosolic and pericellular Ca2+ signalling elicited in the 
absence of extracellular Ca2+.  Prior to the performance of Ca2+ signalling studies, the effect of 
Gö6976 on thrombin-evoked dense granule secretion was tested using a luciferin-luciferase 
assay. Pretreatment of washed platelet suspensions with 3 μM Gö6976 for 10 minutes at 37°C 
was found to essentially abolish dense granule secretion (6.8% ± 3.3% of control; n = 5; P < 
0.05). Thrombin-evoked Ca2+ release was also found to be significantly potentiated under these 
conditions in fura-2-loaded platelet samples from the same donor (178.6 ± 19.3% of control; n 
= 10; P < 0.05; Figure S5C), suggesting that Ca2+ removal and sequestration systems were both 
inhibited in line with to other recent findings (Lever et al., manuscript in submission). If Ca2+ 
exocytosis from the dense granules into the pericellular space was a prerequisite for Ca2+ store 
mobilisation into the cytosol via pericellular recycling, then Gö6976 would be expected to 
significant inhibit, and not enhance, the Ca2+ signal observed.  These data therefore suggest 
that intracellular Ca2+ release from the intracellular stores occurs only directly via Ca2+ exit 
from the stores through open IP3 and NAADP receptors (Sage et al., 2011), and not indirectly 
via the extracellular space. 
Despite the effect of  Gö6976-treated on the  thrombin-evoked cytosolic Ca2+ signal, cells could 
be seen to form pericellular hotspots in 81.6 ± 5.5% of Gö6976-treated cells which was not 
significantly different to the 92.3% ± 2.3% observed in DMSO-treated cells (Figure S5D; n = 
6; P > 0.05).  Although these hotspots were seen on half of the occasions to have a notable 
reduction in fluorescent intensity, this effect was inconsistent and only seen in 3/6 experiments. 
However despite this, the continued appearance of pericellular hotspots in all samples of 
Gö6976-treated cells suggest that dense granule secretion is not principally responsible for the 
formation of the pericellular Ca2+ hotspot. 
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